APTOF
Aptose Biosciences Inc.
Next earnings Aug 11, 2026
Last earnings -0.6% on 2026-05-13
$1.55
▲ +1.31%$1.55▲ +61.46%
over 1Y
L $0.80EODHDH $1.85
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.3%
1W+4.0%
1M-7.7%
3M-3.7%
YTD+0.6%
1Y+61.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
High return on equity (93.7%).
Aptose Biosciences Inc. shows $0.00 in FY2025 revenue, and 93.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | -$65.4M | -$41.8M | -$51.2M | -$25.4M | -$25.5M |
| Diluted EPS | -$0.73 | -$6.80 | -$227.43 | -$36.38 | -$10.41 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$3.02M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-643.7%
FCF yield-555.8%
Quality & risk
ROIC (est.)—
Free cash flow-$22.0M
Total debt—
Net cash$935K
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-152026-06-15open ↗8-KPeriod ending 2026-05-292026-05-29open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-132026-05-13open ↗8-KPeriod ending 2026-04-302026-04-30open ↗SC 13E3/AFiling2026-04-01open ↗10-KPeriod ending 2025-12-312026-03-31open ↗8-KPeriod ending 2026-03-312026-03-31open ↗8-KPeriod ending 2026-03-312026-03-31open ↗RWFiling2026-03-23open ↗8-KPeriod ending 2026-03-122026-03-23open ↗8-KPeriod ending 2026-03-232026-03-23open ↗
Frequently asked
- Is Aptose Biosciences Inc. (APTOF) a buy?
- APTOF currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (93.7%).
- What is Aptose Biosciences Inc.'s quality score?
- APTOF scores 27.5/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000882361, latest 10-Q filed 2026-05-13) · EODHD · as of 6/22/2026, 11:30:03 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.